Novartis and Hybridon to Develop Oligonucleotides for Asthma and Allergy
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 61 (Table of Contents)
Published: 5 Jul-2005
DOI: 10.3833/pdr.v2005.i61.651 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Novartis entered a second high-value collaborative R&D deal for inflammatory disease with Hybridon to develop oligonucleotide candidates for the treatment of asthma and allergy using Hybridon’s immune modulatory oligonucleotide (IMO™) technology platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS